Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Kiniksa Pharmaceuticals	Mersana Therapeutics	Stoke Therapeutics	Omeros	Praxis Precision Medicines
Symbol	NASDAQ:KNSA	NASDAQ:MRSN	NASDAQ:STOK	NASDAQ:OMER	NASDAQ:PRAX
Price Information
Current Price	$14.58	$15.01	$33.52	$17.71	$26.54
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.2	1.5	1.4	1.7
Analysis Score	3.5	3.4	3.4	3.3	3.5
Community Score	2.4	2.7	3.0	3.0	4.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	0.0	0.8	0.8	0.0
Earnings & Valuation Score	0.0	0.0	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$37.00	$26.17	$64.33	$23.00	$60.33
% Upside from Price Target	153.77% upside	74.33% upside	91.93% upside	29.87% upside	127.33% upside
Trade Information
Market Cap	$998.23 million	$1.06 billion	$1.19 billion	$1.11 billion	$1.08 billion
Beta	0.03	2.54	0.63	1.65	N/A
Average Volume	478,515	947,931	176,668	697,662	171,567
Sales & Book Value
Annual Revenue	N/A	$42.12 million	N/A	$111.81 million	N/A
Price / Sales	N/A	24.61	N/A	9.87	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.10 per share	$1.64 per share	$6.86 per share	($2.19) per share	N/A
Price / Book	N/A	9.15	N/A	-8.09	N/A
Profitability
Net Income	$-161,870,000.00	$-28,210,000.00	$-32,330,000.00	$-84,490,000.00	N/A
EPS	($2.99)	($0.65)	($1.80)	($0.96)	N/A
Trailing P/E Ratio	N/A	N/A	N/A	N/A	0.00
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-8,772.91%	N/A	-134.59%	N/A
Return on Equity (ROE)	-53.65%	-45.16%	-22.93%	N/A	N/A
Return on Assets (ROA)	-49.11%	-37.53%	-22.26%	-59.49%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.02%	N/A	N/A	N/A
Current Ratio	15.20%	13.05%	29.02%	4.11%	N/A
Quick Ratio	15.20%	13.05%	29.02%	4.07%	N/A
Ownership Information
Institutional Ownership Percentage	42.00%	N/A	N/A	56.63%	N/A
Insider Ownership Percentage	70.63%	5.30%	54.60%	11.30%	N/A
Miscellaneous
Employees	168	110	79	277	67
Shares Outstanding	68.23 million	69.05 million	36.70 million	62.33 million	38.63 million
Next Earnings Date	7/29/2021 (Estimated)	5/10/2021 (Confirmed)	5/21/2021 (Estimated)	5/10/2021 (Confirmed)	6/16/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Praxis Precision Medicines (NASDAQ:PRAX) Sees Strong Trading Volume americanbankingnews.com - May 7 at 11:54 AM
	Should You Take Comfort From Insider Transactions At Praxis Precision Medicines, Inc. (NASDAQ:PRAX)? nasdaq.com - May 3 at 12:46 PM
	Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down to $32.22 americanbankingnews.com - May 3 at 12:06 PM
	William Blair Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX) americanbankingnews.com - May 3 at 10:10 AM
	Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Metrics You Need to Know Right Now stocksregister.com - May 1 at 1:24 PM
	Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 11.2% americanbankingnews.com - April 30 at 11:39 AM
	Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE ca.finance.yahoo.com - April 30 at 9:58 AM
	Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE finance.yahoo.com - April 30 at 9:58 AM
	Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 5.3% americanbankingnews.com - April 29 at 2:54 PM
	Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D. finance.yahoo.com - April 29 at 12:53 PM
	Praxis Precision Medicines (NASDAQ:PRAX) Sees Large Volume Increase americanbankingnews.com - April 27 at 11:38 AM
	Why Praxis Precision Medicine's Stock is Up During Today's Session benzinga.com - April 26 at 5:55 PM
	Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.7% americanbankingnews.com - April 23 at 1:36 PM
	Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Up to $25.97 americanbankingnews.com - April 22 at 11:34 AM
	Praxis Precision Medicines (NASDAQ:PRAX) Trading 8.3% Higher americanbankingnews.com - April 21 at 1:38 PM
	Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer apnews.com - April 20 at 8:56 AM
	Praxis Precision Medicines, Inc. Common Stock (PRAX) nasdaq.com - April 20 at 12:21 AM
	Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation finance.yahoo.com - April 19 at 7:20 PM
	Praxis Precision Medicines Inc (PRAX) uk.investing.com - April 17 at 12:02 AM
	Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of ... apnews.com - April 15 at 7:35 PM
	Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D. finance.yahoo.com - April 15 at 7:35 PM
	Praxis Precision Medicines (NASDAQ:PRAX) Trading 4.5% Higher americanbankingnews.com - April 15 at 11:37 AM
	Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Up 129.1% in March americanbankingnews.com - April 15 at 1:06 AM
	Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE finance.yahoo.com - April 14 at 1:23 PM
	Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day finance.yahoo.com - March 24 at 10:27 AM

Date	Company	Brokerage	Action
11/24/2020	Kiniksa Pharmaceuticals	Evercore ISI	Initiated Coverage
6/30/2020	Kiniksa Pharmaceuticals	The Goldman Sachs Group	Boost Price Target
6/29/2020	Kiniksa Pharmaceuticals	Bank of America	Boost Price Target
6/29/2020	Kiniksa Pharmaceuticals	Wedbush	Boost Price Target
3/11/2020	Kiniksa Pharmaceuticals	JPMorgan Chase & Co.	Boost Price Target
8/14/2019	Kiniksa Pharmaceuticals	JMP Securities	Lower Price Target
3/11/2019	Kiniksa Pharmaceuticals	Barclays	Initiated Coverage
3/30/2021	Mersana Therapeutics	Credit Suisse Group	Initiated Coverage
12/2/2020	Mersana Therapeutics	Stifel Nicolaus	Initiated Coverage
11/9/2020	Mersana Therapeutics	SVB Leerink	Boost Price Target
6/24/2020	Mersana Therapeutics	BTIG Research	Boost Price Target
6/23/2020	Mersana Therapeutics	HC Wainwright	Reiterated Rating
5/28/2020	Mersana Therapeutics	Robert W. Baird	Boost Price Target
1/13/2020	Mersana Therapeutics	Cowen	Reiterated Rating
3/17/2021	Stoke Therapeutics	Canaccord Genuity	Boost Price Target
1/14/2021	Stoke Therapeutics	Needham & Company LLC	Boost Price Target
10/23/2020	Stoke Therapeutics	Cantor Fitzgerald	Initiated Coverage
2/1/2021	Omeros	UBS Group	Initiated Coverage
12/4/2020	Omeros	Maxim Group	Boost Price Target
5/3/2021	Praxis Precision Medicines	William Blair	Initiated Coverage
11/10/2020	Praxis Precision Medicines	Piper Sandler	Initiated Coverage

(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources